Navigation Links
Five New Clinical Studies Show Value of Masimo PVI & PI
Date:10/17/2008

Data to be presented at American Society of Anesthesiologists Annual

Meeting as Masimo showcases world's first-and-only noninvasive and continuous hemoglobin (SpHb) and Oxygen Content (SpOC) monitor with live

booth demonstrations

IRVINE, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Masimo, the inventor of Pulse CO-Oximetry(TM) and Measure-Through-Motion-and-Low-Perfusion pulse oximetry, announced today that five new independent and objective studies demonstrating Masimo PVI to be highly predictive of patient fluid status will be presented at the American Society of Anesthesiology (ASA) Annual Meeting in Orlando, Fla., October 19-21, 2008.

Fluid administration is critical to optimizing patient status and enabling end organ preservation, but traditional methods to guide fluid administration are invasive and often fail to predict fluid responsiveness. PVI has been shown to predict fluid responsiveness in mechanically ventilated patients under general anesthesia during surgery, and may help clinicians optimize fluid administration and improve patient outcomes.(2-4)

Also at ASA for the first time, Masimo will be showcasing live demonstrations of the first-ever noninvasive and continuous hemoglobin (SpHb) and Oxygen Content (SpOC) monitor. SpHb provides instantaneous hemoglobin measurements that may facilitate faster, easier, safer, and better clinical decisions by allowing clinicians to more quickly detect chronic or acute anemia, identify occult bleeding earlier, and more effectively manage blood transfusions. While oxygen saturation (SpO2) and hemoglobin are considered critical parameters for patient management, neither parameter by itself can indicate the actual amount of oxygen in the blood. However, now with Masimo Rainbow SET Pulse CO-Oximetry, SpHb and SpO2 can be used together to provide clinicians with the first-and-only technology for real-time and noninvasive oxygen content (SpOC(TM)) monitoring,
'/>"/>

SOURCE Masimo
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
2. Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society
3. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
4. Sysmex Announces Clinical Laboratory Software Name Change
5. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Covance Decides to Pursue Its Original Preclinical Strategy in China
8. Satyam Partners with Oracle to Provide Clinical Development Applications
9. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
10. Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
11. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Dendreon Appoints Hans Bishop as Chief Operating Officer 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6
Other Biology Technology:Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 6BMP Sunstone Reports Third Quarter 2008 Financial Results 2BMP Sunstone Reports Third Quarter 2008 Financial Results 3BMP Sunstone Reports Third Quarter 2008 Financial Results 4BMP Sunstone Reports Third Quarter 2008 Financial Results 5BMP Sunstone Reports Third Quarter 2008 Financial Results 6BMP Sunstone Reports Third Quarter 2008 Financial Results 7BMP Sunstone Reports Third Quarter 2008 Financial Results 8BMP Sunstone Reports Third Quarter 2008 Financial Results 9BMP Sunstone Reports Third Quarter 2008 Financial Results 10BMP Sunstone Reports Third Quarter 2008 Financial Results 11BMP Sunstone Reports Third Quarter 2008 Financial Results 12BMP Sunstone Reports Third Quarter 2008 Financial Results 13BMP Sunstone Reports Third Quarter 2008 Financial Results 14Endocare Reports Financial Results for Third Quarter 2008 2Endocare Reports Financial Results for Third Quarter 2008 3Endocare Reports Financial Results for Third Quarter 2008 4Endocare Reports Financial Results for Third Quarter 2008 5Endocare Reports Financial Results for Third Quarter 2008 6Endocare Reports Financial Results for Third Quarter 2008 7Endocare Reports Financial Results for Third Quarter 2008 8Endocare Reports Financial Results for Third Quarter 2008 9Endocare Reports Financial Results for Third Quarter 2008 10Endocare Reports Financial Results for Third Quarter 2008 11